GlassScriptPhysician profile
Zeeshan Fatima Syed
NPI 1295861631
$1,177.91
in general payments reported to CMS, 2019-2025
12 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $106 · 2021: $25.90 · 2022: $70.90 · 2023: $221 · 2024: $250 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702 · Education: $49.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.56 |
| Education | $49.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.76 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $199.39 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $101.74 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $93.73 | 2023 | Jynarque |
| Fresenius USA Marketing, INC. | $92.79 | 2019-2025 | Velphoro |
| Vifor Pharma, INC. | $87.14 | 2019-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $85.71 | 2022-2025 | |
| Travere Therapeutics, INC. | $72.32 | 2022-2025 | |
| Akebia Therapeutics INC | $37.23 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.69 | 2022-2025 | Ultomiris |
| Novo Nordisk INC | $20.53 | 2022 | |
| Genentech USA, INC. | $14.88 | 2025 | Gazyva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.